The complaint investigation for false non-reactive results for one sample tested with the architect havab igm assay included a review of data and information provided by the customer, search for similar complaints, ticket trending review, labeling review, device history record review and testing of retained kits with the complaint lot numbers.Trending review determined no adverse trend for the issue for the product.Device history record review did not identify any non-conformances or deviations with the likely cause lot and complaint issue.Inhouse testing of retained kits of the complaint lot number and testing of a commercially available seroconversion panel (biomex scp-hav-001) determined that the sensitivity performance is not negatively impacted.Based on the investigation, no systemic issue or deficiency with the architect havab igm reagent lot was identified.
|